Immunomodulating Nanomedicine for Cancer Therapy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 30185039.
- Also identified by DOI 10.1021/acs.nanolett.8b02340 and PMC identifier 6238186.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Nanomaterials offer unique advantages as drug-delivery vehicles for cancer therapeutics. For immuno-oncology applications, cancer nanomedicine should be developed beyond drug-delivery platforms. A greater emphasis on actively modulating host anticancer immunity using nanomaterials provides new avenues for developing novel cancer therapeutics.
Medical subject headings
- Drug Delivery Systems
- Immunomodulation
- Nanomedicine
- Nanostructures
- Neoplasms